Pharmaceuticals News and Research

RSS

New technique offers hope for stroke sufferers

If a stroke patient doesn't get treatment within approximately the first three hours of symptoms, there's not much doctors can do to limit damage to the brain.

25 Aug 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Meda settles U.S. Astelin patent litigation with Cobalt

Meda, through its wholly owned U.S. subsidiary, Meda Pharmaceuticals Inc., has entered into a settlement agreement with Cobalt Pharmaceuticals Inc. (hereafter Cobalt) that resolves the U.S. patent litigation between the companies regarding Cobalt's proposed generic version of Astelin.

25 Aug 2008

Good tidings for women on HRT

For many women struggling to deal with the symptoms of the menopause, the latest research on hormone replacement therapy (HRT) bears good tidings.

25 Aug 2008

Infant deaths in clinical drug trials in India raise concern about ethical standards

The revelation that 49 babies died at a top Indian hospital during drug tests has shocked many and raised issues concerning ethical standards at the hospital.

25 Aug 2008

OncoGenex Pharmaceuticals' OGX-011 granted FDA fast track status

OncoGenex Pharmaceuticals has announced that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer.

24 Aug 2008

New imaging technology provides early diagnosis of osteoarthritis

A newly developed medical imaging technology may provide doctors with a long-awaited test for early diagnosis of osteoarthritis (OA), scientists from New York reported today at the 236th National Meeting of the American Chemical Society.

20 Aug 2008

Eli Lilly acquires SGX Pharmaceuticals

Eli Lilly and Company has announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. (Public, NASDAQ:SGXP), a San Diego-based biotechnology company focused on drug discovery and development in the area of oncology.

20 Aug 2008

Addiction drug Vigabatrin proves successful in animal weight loss study

Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group.

20 Aug 2008

Stanford develop method to overcome multiple drug resistant diseases

Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.

18 Aug 2008

Researchers create synthetic heparin

Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin. At the national conference of the American Chemical Society on August 17, 2008, Linhardt announced that his research team may have accomplished this task by building the first fully synthetic heparin. Their creation is the largest dose of heparin ever created in the lab.

17 Aug 2008

Spice-based compound to fight against cancer

Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading.

17 Aug 2008

FDA approves tetrabenazine for Huntington's disease

The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.

17 Aug 2008

URMC & NIH partner to expand, accelerate clinical research in neurological diseases

The University of Rochester Medical Center (URMC) and the National Institute of Neurological Disorders and Stroke are hosting a week-long training session designed to create a new generation of researchers with the specialized skills necessary to conduct clinical trials in neurological disorders.

14 Aug 2008

Watson announces ruling in Naproxen sodium patent case

Watson Pharmaceuticals, Inc. announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan, infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent").

13 Aug 2008

Isis Pharmaceuticals trials C-reactive protein drug

Isis Pharmaceuticals, Inc. announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease.

13 Aug 2008

Diakron licenses anticoagulant drug candidate from Merck

Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

13 Aug 2008

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.

12 Aug 2008

IMPAX sued for patent infringement on generic Ultram ER

IMPAX Laboratories, Inc. today announced Purdue Pharma Products L.P. ("Purdue"), Napp Pharmaceutical Group Ltd. ("Napp"), Biovail Laboratories International, SRL ("Biovail") and Ortho-McNeil, Inc. ("Ortho-McNeil") have filed suit for patent infringement in the United States District Court for the District of Delaware based on the Company's submission of its Abbreviated New Drug Application ("ANDA") for tramadol hydrochloride extended-release tablets (100 mg), generic of Ultram ER, to the Food and Drug Administration.

12 Aug 2008

Low vitamin D levels substantially increase risk of death

Researchers at Johns Hopkins are reporting what is believed to be the most conclusive evidence to date that inadequate levels of vitamin D, obtained from milk, fortified cereals and exposure to sunlight, lead to substantially increased risk of death.

11 Aug 2008